LeadXpro and Alipheron search for molecules to develop new drugs

Back

Villigen/Dornach - LeadXpro and Alipheron have entered into a partnership, combining their strengths in structural biology and virtual screening of combinatorial libraries with trillions of molecules. They hope this will accelerate discovery of new therapeutics.

LeadXpro, based in Park Innovaare in Villigen, and Alipheron, located in Dornach, are set to work together in future. According to a press release, this partnership will combine leadXpro’s extensive expertise in structural biology with Alipheron’s innovative software suite, enabling virtual screening of ultra-large combinatorial libraries.

The goal of the partnership is to develop a protein-structure-driven virtual screening approach on ultra-large combinatorial libraries, as an alternative to traditional high-throughput screening in drug discovery. In the statement, leadXpro describes this as a groundbreaking approach.

“This collaboration will allow us to leverage our strengths in structural biology and virtual screening,” says Luboš Remeň, Director of Lead Medicinal Chemistry at leadXpro, summarizing the motivation of the two companies. “This will ultimately speed up the discovery of new molecules and accelerate the development of new and effective therapeutics.”

Modest von Korff, CEO of Alipheron, is also confident that the collaboration will offer added value: “Partnering with leadXpro aligns perfectly with our mission to provide superior software that drives scientific innovation.” ce/mm